Shares of Lakewood-Amedex Biotherapeutics, Inc. (LABT) more than doubled on Wednesday morning after highlighting new data showing its lead antimicrobial candidate, Nu-3, demonstrated a high barrier to bacterial resistance, aligning with U.S. efforts to combat antimicrobial resistance.
The stock is currently trading at $3.8601, up $2.0001 or 107.52%, on the Nasdaq. It opened at $6.5000 after closing the previous session at $1.8600. The stock has traded between $1.6600 and $98.2000 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.